-
Product Insights
Neuroblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroblastoma - Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Liposarcoma - Drugs In Development, 2023’, provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of...
-
Product Insights
Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADPA-2M4CD8 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADPA-2M4CD8 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADPA-2M4CD8 in Fallopian Tube Cancer Drug Details: ADP-A2M4CD8 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-0742 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-0742 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-0742 in Small-Cell Lung Cancer Drug Details: KB-0742 is under...
-
Company Profile
Adaptimmune Ltd – Company Profile
Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics plc is a biopharmaceutical company. It includes developing T-cell receptors for T-cell therapy and SPEAR TCR therapies to utilize the body’s immune system. Adaptimmune’s product pipeline includes ADP-A2M10 (MAGE-A10) for melanoma, urothelial cancer, ADP-A2M4 (MAGE-A4) for synovial sarcoma, myxoid cell liposarcoma, ovarian cancer, ADP-A2AFP (AFP) for liver cancer. Its clinical trials include multiple myeloma trial, synovial sarcoma trial, ovarian cancer trial, non-small cell lung cancer (NSCLC). The company also provides pre-clinical testing...
Add to Basket